scholarly journals Correction to: Lag times to steady state drug delivery by continuous intravenous infusion: direct comparison of peristaltic and syringe pump performance identifies contributions from infusion system dead volume and pump startup characteristics

2022 ◽  
Author(s):  
Lauren E. Gibson ◽  
Anders S. Knudsen ◽  
David Arney ◽  
Hao Deng ◽  
Nathaniel M. Sims ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Steady State ◽  
Intravenous Infusion ◽  
Dead Volume ◽  
Continuous Intravenous Infusion ◽  
Syringe Pump ◽  
Pump Performance ◽  
Lag Times ◽  
Infusion System

Computer Control of Drug Delivery by Continuous Intravenous Infusion

2015 ◽  
Vol 122 (3) ◽  
pp. 647-658 ◽  
Author(s):  
Michael J. Parker ◽  
Mark A. Lovich ◽  
Amy C. Tsao ◽  
Abraham E. Wei ◽  
Matthew G. Wakim ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Steady State ◽  
Intravenous Infusion ◽  
Computer Control ◽  
Dead Volume ◽  
Dominant Factor ◽  
Drug Infusion ◽  
Temporal Lags

Abstract Background: Intravenous drug infusion driven by syringe pumps may lead to substantial temporal lags in achieving steady-state delivery at target levels when using very low flow rates (“microinfusion”). This study evaluated computer algorithms for reducing temporal lags via coordinated control of drug and carrier flows. Methods: Novel computer control algorithms were developed based on mathematical models of fluid flow. Algorithm 1 controlled initiation of drug infusion and algorithm 2 controlled changes to ongoing steady-state infusions. These algorithms were tested in vitro and in vivo using typical high and low dead volume infusion system architectures. One syringe pump infused a carrier fluid and a second infused drug. Drug and carrier flowed together via a manifold through standard central venous catheters. Samples were collected in vitro for quantitative delivery analysis. Parameters including left ventricular max dP/dt were recorded in vivo. Results: Regulation by algorithm 1 reduced delivery delay in vitro during infusion initiation by 69% (low dead volume) and 78% (high dead volume). Algorithmic control in vivo measuring % change in max dP/dt showed similar results (55% for low dead volume and 64% for high dead volume). Algorithm 2 yielded greater precision in matching the magnitude and timing of intended changes in vivo and in vitro. Conclusions: Compared with conventional methods, algorithm-based computer control of carrier and drug flows can improve drug delivery by pump-driven intravenous infusion to better match intent. For norepinephrine infusions, the amount of drug reaching the bloodstream per time appears to be a dominant factor in the hemodynamic response to infusion.

scholarly journals Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure

2005 ◽  
Vol 49 (8) ◽  
pp. 3550-3553 ◽  
Author(s):  
Federico Pea ◽  
Pierluigi Viale ◽  
Daniela Damiani ◽  
Federica Pavan ◽  
Francesco Cristini ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Acute Myeloid Leukemia ◽  
Steady State ◽  
Intravenous Infusion ◽  
Myeloid Leukemia ◽  
Continuous Intravenous Infusion ◽  
Pharmacokinetic Variability ◽  
Pharmacodynamic Profile ◽  
Neutropenic Patients ◽  
Acute Myeloid

ABSTRACT The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.

PROLONGED INTRAVENOUS INFUSION OF LABELLED IODOCOMPOUNDS IN THE RAT: [125I]THYROXINE AND [125I]TRI-IODOTHYRONINE METABOLISM AND EXTRATHYROIDAL CONVERSION OF THYROXINE TO TRI-IODOTHYRONINE

1979 ◽  
Vol 82 (2) ◽  
pp. 235-241 ◽  
Author(s):  
VIPA BOONNAMSIRI ◽  
J. C. KERMODE ◽  
B. D. THOMPSON
Keyword(s):  
Steady State ◽  
Thin Layer ◽  
Thin Layer Chromatography ◽  
Intravenous Infusion ◽  
Total Production ◽  
Continuous Intravenous Infusion ◽  
Faecal Excretion ◽  
Layer Chromatography

SUMMARY Extrathyroidal tissues of the rat were labelled to steady state by prolonged continuous intravenous infusion of 125I-labelled thyroxine (T4) or tri-iodothyronine (T3). Labelled iodocompounds extracted from various tissues were analysed by thin-layer chromatography. Significant amounts of labelled T3 were found in all tissues examined after infusion of [125I]T4, confirming that conversion of T4 to T3 occurs in extrathyroidal tissues of the rat. Faecal excretion of labelled T3 after [125I]T4 infusion provided an assessment of the extent of extrathyroidal conversion: about a third of the T4 was metabolized by this pathway. Extrathyroidal conversion was independently estimated to account for about a third of the total production of T3. The site of extrathyroidal conversion was established by comparing the distributions of labelled T3 after the two types of infusion: kidney and liver were both prominent sites of conversion of T4 to T3.

Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

2020 ◽  
Vol 1 (30) ◽  
pp. 30-36
Author(s):  
E. A. Krylova ◽  
D. V. Aleinik
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Intravenous Infusion ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Continuous Intravenous Infusion ◽  
Endoscopic Retrograde ◽  
Pancreatic Enzyme Secretion

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

Sign in / Sign up

Export Citation Format

Share Document